[
  {
    "ts": null,
    "headline": "Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress",
    "summary": "mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating ...",
    "url": "https://finnhub.io/api/news?id=0290b43c1024fc134579962c024b2fab85f6e6192c9e2839236f529f90745e00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760306700,
      "headline": "Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress",
      "id": 137063943,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating ...",
      "url": "https://finnhub.io/api/news?id=0290b43c1024fc134579962c024b2fab85f6e6192c9e2839236f529f90745e00"
    }
  }
]